Sunday, January 11, 2015 1:10:20 PM
#1 - 29 per cent gain in one day is NOT overpumped if the news has substance. This isn't fluff - it's 60 million upfront and up to 350 million if it reaches various milestones.
#2 - Shingles vaccine alone with a 97 per cent effective rate will bring in huge revenue streams.
#3 - Several upgrades all at 10.00 or more coming in Friday. They all know how big of a deal this is.
#4 - You can expect more upgrades as this news digests. One upgrade came in when the company was at 4.91 on Friday and heavy buying took it all the way back up to 5.50 range immediately.
#5 - Afterhours, Jimmy Cramer is telling everyone this is the last chance to get in at these prices. He could not contain his excitement when he had CEO Garo on his show because he knows this is a blockbuster here.
#6 - Institutional investment coming in as this is over 5.00 range - just starting to build their positions. You can expect more money coming in very soon.
#7 - This is only the second day of the run - looking for 3 good days here.
#8 - This will be extremely volatile and is officially in play. There is quite a buzz here and you can expect runs throughout the day, both up and down but trending higher as more people believe in this as a long term investment and not a quick trade. I am looking at the 5.20 level as the floor but not quite sure how high this can or will go from here. I do believe this will eventually be much, much higher from here.
Recent AGEN News
- Contact The Gross Law Firm by November 5, 2024 Deadline to Join Class Action Against Agenus Inc.(AGEN) • PR Newswire (US) • 09/19/2024 09:45:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) Shareholders • PR Newswire (US) • 09/16/2024 09:45:00 AM
- Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024 • Business Wire • 09/13/2024 02:00:00 PM
- Edelson Lechtzin LLP Urges Agenus, Inc. (NASDAQ: AGEN) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action • PR Newswire (US) • 09/11/2024 06:25:00 PM
- Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 • Business Wire • 09/09/2024 11:30:00 AM
- Agenus to Participate in September Investor Conferences • Business Wire • 09/03/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:49:59 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/08/2024 08:47:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:45:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:45:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:08:46 PM
- Agenus Reports Second Quarter 2024 Operational and Financial Results • Business Wire • 08/08/2024 11:00:00 AM
- Agenus Announces Appointment of Tom Harrison to Board of Directors • Business Wire • 08/08/2024 11:00:00 AM
- Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers • Business Wire • 08/07/2024 02:58:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:02:09 PM
- Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update • Business Wire • 07/26/2024 11:00:00 AM
- Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer • Business Wire • 07/18/2024 11:00:00 AM
- Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference • Business Wire • 06/28/2024 03:10:00 PM
- Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies • Business Wire • 06/27/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:05:01 PM
- Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors • Business Wire • 06/17/2024 11:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM